Drugs / Cu-DOTA-ECL1i
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03492762 | Feb 2018 → Dec 2027 expected | pneumonitis | Washington University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cu-DOTA-ECL1i | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03492762 ↗ |
| Modality | Diagnostic / imaging agent | “a radiotracer to noninvasively track CCR2+ monocytes and macrophages using positron emission tomography (PET)” PMID 32673071 ↗ Jan 2021 |
| Target | CCR2 | “Radiolabeled probe called Cu-DOTA-ECL1i that recognizes CCR2” NCT03492762 ↗ |